Skyes Chief Executive Officer, Punit Dhillon, commented on the important mechanistic advantages of nimacimab versus other CB1 inhibitors highlighted in this video update series: Obesity isnt just a public health crisis, its a biologically defended state, one that resists traditional treatments requiring smarter and safer interventions
A clinical review published on PubMed confirmed that cortisol and prolactin remained stable at therapeutic doses, distinguishing ipamorelin from GHRP-2 and GHRP-6 on safety grounds
The proteomics technology developments applied was part of a project that has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreements: MSmed-686547, EPIC-XS-823839, and ERC synergy grant 810057-HighResCells
Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al